Physician profile
Amer Husseini
NPI 1578544664
$1,203.24
in general payments reported to CMS, 2019-2025
12 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2022: $13.68 · 2023: $262 · 2024: $410 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.74 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $250.18 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $120.87 | 2024-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $100.75 | 2023-2025 | Farxiga |
| Novo Nordisk INC | $93.04 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $86.97 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.71 | 2019 | |
| Edwards Lifesciences Corporation | $27.42 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $23.05 | 2024 | Mounjaro, Zepbound |
| Amgen INC. | $19.98 | 2024 | Repatha |
| Esperion Therapeutics, INC. | $17.17 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $16.36 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Husseini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.